U.S. Markets closed

Interpace Biosciences, Inc. (IDXG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
8.69+0.09 (+1.05%)
At close: 3:58PM EDT
Sign in to post a message.
  • I
    Improvement in Medicare reimbursement, additional managed care coverage + OPEX SG&A stripped out from prior management acquisition, stock will continually improve with additional testing on ThyGeNEXT®, ThyraMIR® . Current Fair value around $11-$13 w/ assumption of EBITDA at roughly $8.0M for 2022.
  • D
    Dave A
    Vanguard MF Manager sold all of its small number of shares (80,612) in the last 20 days, Fidelity all of their measly 30K shares sometime since 1/1/21. I'm out.
  • b
    a little news would go along way here.....
  • a
    Great conference call today. Best way is to hold this stock. Great buyout candidate and lot of backlog revenue from medi-care coming in. Any price under $12 is great. Target would be around $18-20
  • M
    This "Compliance and Audit" issue is probably why they had this large $5 Million accounts receivables problem that they were continually having "trouble" collecting on. Maybe because the Revenue never really existed, and the Accrual versus Cash Accounting switch bought them some time. Also suspicious that the CFO only recently left the company within the last couple months right before this happens...my suspicion is he is one of the Employees they mention in the 8-k. Company is also running out of money by year end as per the financials , but they wont be able to raise cash while an investigation is ongoing ...hence they will be a "Going Concern". This is probably a serious accounting issue , they may also have to restate not one but multiple quarters given how far back their Accounts Receivable problems go back ...we will see
  • b
    this company is going to get bought out.....
  • K
    Thank goodness Jack Stover is gone. We finally have good management that will be able to create value for the shareholders. Jack never seemed to care about the shareholders, just his job, salary, lifestyle (boat). With a $10/share average price, I am still a long way from break-even, but today feels better than yesterday!
  • J
    For the record, with 4 million shares outstanding, the street is valuing Interpace's technology at $12,000,000. Some pharma companies are spending $1 to $10 BILLION to develop reliable tests. This company is ripe for a buyout, and it won't be at $3.00 per share.

    Just my opinion.
  • J
    Happy Thanksgiving guys. Remember every new day brings renewed hope. These dull days shall past and bright ones on the horizon shall pervade the grounds again. Money ebbs and flows like the tides. There is always plenty for everyone.SOMETIMES YOU JUST HAVE TO WAIT A LITTLE LONGER FOR IT. Enjoy you Thanksgiving Holiday. Life is short and not worth the aggrivation. HUG YOUR FRIENDS. AND FAMILIES AND TELL THEM THAT YOU LOVE THEM.
  • S
    well idxg longs. it was a truly beautiful week. we broke thru 1.45 resistance early and held it nearly the entire trading session. there are only buyers from here to 1.90
    I'm thinking 2 weeks we're. there.
  • S
    Schonfeld Strategic Advisors LLC has disclosed a new 225K position in IDXG.
  • S
    hearing buyout at 45 million - this translates to a share price of $11.13
  • I
    Informed Observer
    Ampersand Capital and 1315 Capital appear to be important drivers of change and are not wasting time rebuilding the IDXG management team in their image… a clear positive development.

    New CFO Knechtel was most recently the CFO of GENEWITZ (a genomics service company with a bioinformatics business). GENEWITZ was one of Ampersand Capital’s portfolio companies which Ampersand ultimately sold to Brooks Automation. Knechtel has been vetted by Ampersand and has turned around and sold businesses.

    New Board Member Rocca (appointed by 1315 Capital) has complimentary proprietary testing sector expertise and his Company (Exagen – XGN) might ultimately be interested in IDXG.

    New VP of Managed Care and Payer Relations Salzman worked for Quest Diagnostics in a similar capacity and brings demonstrated competence to bear in these areas. The latter will presumably be of greater importance to IDXG given Medicare’s (MAC) draft and hopefully ultimate local coverage determination (LCD), sometime this quarter.
  • J
    The intrinsic value of this stock by all measures is between $2.50 to $3.50. It is where it is because of the short position, but the tide is about to change in our favor.
  • J
    Justin D. Miller
    BarreGEN news on partnership coming soon folks. I am hoping that's why they have been so quiet. medtronic would be my guess on the partner based off mentioning a medical device partner in previous CC
  • n
    today, Wednesday April 22, 2020 at 5:00 p.m. Eastern time. be there for the CC

    The conference call can be accessed as follows:

    Date and Time: Wednesday, April 22, 2020 at 5:00 p.m. ET
    Dial-in Number (Domestic): +1 (877) 407-9716
    Dial-in Number (International): +1 (201) 493-6779
    Confirmation Number: 137025801
    Webcast Access: http://public.viavid.com/index.php?id=139473

    Following the conclusion of the conference call, a replay will be available through May 6, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.interpacediagnostics.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days
    Interpace Biosciences, Inc. Full Year and Fourth Quarter 2019 Financial Results - 1307861
  • O
    Happy New Year! Hoping for better in 2018. With earnings coming in February and possible Barrengen news within the quarter... the next few months should be better than the last few.
  • J
    Ease and press, ease and press and we shall get there eventually. A penny here and a penny there will soon add up to a meaningful number. 25k strong. Revenues should touch 30 million easily this year.
  • M
    At some point, the goodness of this company and it's financial performance is going to be well known whether by a partner, a buyout, or investors (or all of the above). Growing revenue 27% YoY and reducing costs. Net loss over the last 6 months was 7.2M compared to $14.6M from prior period. And 2018 really seems to be set up to achieve even better results. Cash available as of Nov 9 is $16.5M. Increasing sales on the ground as the exposure to larger markets is there, and finally but certainly not least....as stated by the CEO on the call:

    "We are in a very positive position. In fact, we are looking at any potential acquisitions or products. And so I think one of the reasons that we're seeing those opportunities is that our balance sheet is certainly a lot stronger, and we're in a position to be able to execute on those -- on a potential acquisition of products. "

    This not a day-trade or even a weekly trade. All one saavy investor has to do is read the Q3 results which were posted, put in just a little bit of DD and the potential can be seen in this ciompany. Sure, the company has to execute. That's always the risk, right!?! You could have the best players and the highest payroll, and ESPN analysts will think that team could be the champions. But the players have to play to their ability. Interpace HAS TO play to their ability and they have been showing that they are capable. The news is going to get out and I believe the management team has their eye on the ball and a good grasp of where they are headed.

    Risk vs reward....I believe 2018 is the year of the reward. GLTA
  • A
    Good news is this higher reimbursement is almost 50 mil more based on 2019 numbers. Assuming it gets approved in Q1 2020